BIRAC-RDI
LOGIN

Funding Support

Flexible, milestone-linked patient capital support to enable high-impact R&D and innovative indigenous manufacturing.

Nature of Support

  • High-risk, High-impact R&D with transformative outcomes.
  • Innovative Indigenous Manufacturing, including process development and scale-up.
  • Platform Technologies and first-in-class innovations.
Note: Routine or incremental R&D is not prioritised.

Funding Principles

1
Merit-based
2
Impact-oriented
3
National Capability Focused

Financial Instruments

Concessional Loans

Long-term concessional loans for project financing.

Equity

Equity and equity-linked instruments.

Blended

A combination of debt and equity instruments.

Note: Grants or short-term loans are not permissible.

Funding Limits

Max 50% Participation

Financing under BIRAC-RDI shall not exceed 50 percent of the total assessed cost of the project/round. The remaining must be arranged from own resources or commercial sources.

Loan Financing

Calculated as 50% of the project cost for clearly defined deliverables.

Equity Financing

Calculated as 50% of the value of the funding round.

Fund Disbursement

Disbursement is linked to:

  • Execution of agreements & minimum 50% co-funding.
  • Achievement of defined milestones.
  • Compliance with reporting and monitoring requirements.

* BIRAC reserves the right to withhold/suspend disbursements in case of non-compliance.